229961-45-9

Usage

Uses

Used in Oncology:
AGN 194310 is used as an anticancer agent for the treatment of specific cancers, such as breast and colon cancer. Its application is based on its ability to inhibit the c-src enzyme, which plays a pivotal role in cancer cell proliferation and survival. By targeting this enzyme, AGN 194310 can potentially disrupt the signaling pathways that support tumor growth.
Used in Inflammatory and Autoimmune Disease Treatment:
AGN 194310 is used as a therapeutic agent in the management of inflammatory and autoimmune diseases. The application is grounded in its capacity to modulate the c-src pathway, which is implicated in inflammatory responses. By inhibiting this pathway, AGN 194310 may help in reducing inflammation and managing the symptoms associated with these conditions.
Currently, AGN 194310 is undergoing clinical trials to evaluate its safety and efficacy in humans, marking a significant step in its journey from a chemical compound to a potential pharmaceutical intervention.

Upstream product

• 229961-27-7 ethyl 4-<<4-(4-ethylphenyl)-2,2-dimethyl-(2H)-thiochromen-6-yl>ethynyl>-benzoate 
• 696-63-9 4-Methoxybenzenethiol 
• 541-47-9 3-Methylbutenoic acid 
• 111424-51-2 6-methoxy-2,2-dimethyl-thiochroman-4-one 
• 111424-46-5 3-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid 
• 229961-88-0 6-hydroxy-2,2-dimethyl-thiochroman-4-one 
• 229961-87-9 3-(4-methoxy-phenylsulfanyl)-3-methyl-butyric acid chloride 
• 229961-91-5 6-ethynyl-2,2,-dimethylthiochroman-4-one 
• 229961-90-4 2,2-dimethyl-6-trimethylsilanyl-ethynyl-thiochroman-4-one 
• 229961-89-1 2,2-dimethyl-4-oxo-thiochroman-6-yl trifluoromethanesulfonate 
• 229961-22-2 ethyl 4-<(2,2-dimethyl-4-oxo-thiochroman-6-yl)ethynyl>benzoate 
• 229961-23-3 ethyl 4-((2,2-dimethyl-4-trifluorosulfonyloxy-(2H)-thiochromen-6-yl)ethynyl)-benzoate 
• 5798-75-4 Ethyl 4-bromobenzoate 
• 155105-68-3 4-(4-ethylphenyl)-2-methylbut-3-yn-2-ol 

Relevant academic research and scientific papers

From Propargylic Alcohols to Substituted Thiochromenes: Gem-Disubstituent Effect in Intramolecular Alkyne Iodo/hydroarylation

This work describes the 6-endo-dig cyclization of S-aryl propargyl sulfides to afford 2H-thiochromenes. The substitution at the propargylic position plays a crucial role in allowing intramolecular silver-catalyzed alkyne hydroarylation and N-iodosuccinimide-promoted iodoarylation. Additionally, a PTSA-catalyzed thiolation reaction of propargylic alcohols was developed to synthesize the required tertiary S-aryl propargyl ethers. The applicability of merging these two methods is demonstrated by synthesizing the retinoic acid receptor antagonist AGN194310.

METHODS FOR TREATING CHEMOTHERAPY AND RADIATION THERAPY SIDE EFFECTS

A method for treating chemo therapy or radiation therapy side effects in a mammal undergoing chemotherapy and/or radiation therapy, the method comprising a step of administering to the mammal a therapeutically effective amount of a RAR antagonist or RAR i

Methods of treatment during vascular procedures

The invention provides in one embodiment a method for treating vascular trauma. The method can include administering to an individual undergoing vascular trauma an effective amount of a retinoic acid receptor (RAR) antagonist or an RAR inhibitor. The meth

Methods of treating hyperlipidemia

The current invention relates to methods for treating hyperlipidemia in mammals, including humans. More specifically, the current invention relates to the use of retinoid or retinoid derivative that is able to act as an antagonist or inverse agonist of a

Synthesis and biological activity of high-affinity retinoic acid receptor antagonists

This article reports the synthesis and biological activity of new high affinity retinioic acid receptor (RAR) antagonists. The effect of introducing heteroatoms in the bicyclic ring system of the potent dihydronaphthalene RAR antagonist 8, and the variation of the pendant aromatic group on the ability of these compounds to function as RAR antagonists is discussed. The use of binding, transcriptional, and in vivo assays revealed that the 2,2-dimethylthiochromene analogue 59, and the 2,2-dimethylchromene derivative 85, were the most effective in blocking retinoid agonist induced activity. Copyright (C) 1999 Elsevier Science Ltd.